Highest-materiality recent filing
OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP
$30M purchase price for VXM01 IP; payment deferred until first milestone payment under existing license (Phase 2 completion).
OSR Holdings files fairness opinion for $815M VXM01 license deal with BCME
Fairness opinion values VXM01 standalone risk-adjusted NPV at ~$93.4M median; deal offers up to $815M milestone payments, no upfront.
Up to $815M in milestone payments from BCM Europe for VXM01 oral immunotherapy platform (Phase 3-ready VEGFR-2 target).
OSR Holdings eliminates $2.02M warrant overhang via $1.06M note at $1.00 conversion (100% premium)
Retired approx. $2.02M in outstanding warrants via issuance of $1.06M senior secured convertible note to White Lion Capital.
The binding term sheet grants BCM Europe exclusive worldwide rights to VXM01, with OSR Holdings providing up to $30M development financing to Vaximm AG.
OSR Holdings signs binding term sheet for VXM01 license; up to $815M in milestones
Vaximm grants BCME exclusive worldwide license to develop and commercialize VXM01; OSRH is primary recipient of milestone payments.
OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake
Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.
OSR Holdings gets Nasdaq extension to Aug 31, 2026 for $1 bid price
Nasdaq granted additional 180-day period until Aug 31, 2026 to regain minimum $1.00 closing bid price.
Acquisition of Woori IO closed Jan 26, 2026; WORIO becomes indirect wholly-owned subsidiary via share exchange (84,338 OSRK shares for 88,891 WORIO shares).
Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.
Non-binding term sheet with BCM Europe AG for exclusive global license of VXM01 oral cancer immunotherapy.
OSRH acquires WORIO for $10.6M in stock; non-invasive glucose monitoring tech
OSRH subsidiary OSRK to acquire WORIO via share exchange for KRW 15B (~USD 10.6M). WORIO becomes indirect wholly owned subsidiary.
OSR Holdings sued by Chardan Capital Markets for $2.07M and 34,500 shares
Chardan filed action in SDNY on Sept 2, 2025 seeking ~$2,070,000 and 34,500 deferred equity shares.
OSR Holdings receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Sept 5, 2025; common stock bid price below $1.00 for 30 consecutive business days.
OSR Holdings Amends Agreements with White Lion to Require Stockholder Meeting by Sept 19, 2025
Amendment to Note Purchase Agreement requires stockholder meeting before Sept 19, 2025 to approve issuances exceeding 19.99% Nasdaq Exchange Cap.
OSR Holdings enters term sheet to acquire Woori IO for noninvasive glucose monitoring tech
Non-binding term sheet: OSRK to acquire WORIO via share exchange; WORIO shareholders receive OSRK shares convertible into OSRH common stock.
Secured $1,110,000 in convertible notes at 5% interest; first $400,000 due after S-1 filing, second $600,000 after effective date.
OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B
Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).
OSR Holdings enters $80M equity purchase agreement with White Lion Capital
Company may require White Lion to purchase up to $80M of common stock via Rapid or VWAP purchase notices.
OSR Holdings completes reverse merger with OSR Korea; begins trading as OSRH
Issued 16,282,047 shares to acquire ~67% of OSR Korea; total shares outstanding 19,276,978.
OSR Holdings completes business combination with OSR Co., Ltd.; begins trading Feb 18 under OSRH
Business combination with OSR Holdings Co., Ltd. closed on February 14, 2025.
BLAC stockholders approve business combination with OSR Holdings; name change to OSR Holdings, Inc.
All proposals approved at Feb 13 special meeting; 93.95% quorum; 57,821 shares redeemed.
BLAC amends PIPE to remove redemption features; modifies OSR deal put/call terms
PIPE amendment removes redemption features from 222,222 Series A Preferred shares (Toonon, $20M at $90/share).
Charter amended to extend business combination deadline from Nov 14, 2024 to Feb 14, 2025.
Bellevue Life Sciences enters $20M PIPE with Toonon Partners for Series A Preferred Stock
Agreed to issue 222,222 Series A Preferred shares at $90/share to Toonon Partners for $20M total.
Bellevue Life Sciences receives second Nasdaq delisting notice for insufficient public holders
Nasdaq notified company on Aug 20, 2024 that it failed to regain compliance with minimum 300 public holders requirement by Aug 13, 2024 deadline.
Two directors resign; Bellevue Life Sciences not compliant with Nasdaq listing rules
Inchul Chung and Radclyffe Roberts resigned from Board and committees effective June 7, 2024, no dispute.
BLAC amends business combo with OSR Holdings; cuts consideration, removes LBV target
Amended BCA reduces Aggregate Consideration to 24,461,214 shares ($244.6M) from 25,033,961 shares ($250.3M).
Stockholders approved charter amendment to extend deadline from May 14 to Nov 14, 2024.
BLAC urges stockholders to vote for extension to Nov 14, 2024; meeting reconvenes May 14
Special meeting reconvened May 14, 2024 to vote on extending business combination deadline to Nov 14, 2024.
On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately.
Kuk Hyoun Hwang is the President and Chief Executive Officer of the Company
David J. Yoo resigned from his position as BLAC's Chief Financial Officer.
Gihyoun Bang is Chief Financial Officer
Sang Hoon Kim is Head of Corporate Venture Capital
Jun Chul Whang is Chief Legal Officer and Secretary
On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.
On June 7, 2024, Radclyffe Roberts also provided notice of his resignation as member of the Board and as a member of the Board’s Compensation Committee (the “Compensation Committee”) as well as a member and chair of the Board’s M&A Committee.
On June 7, 2024, Inchul Chung provided notice of his resignation as a member of the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) and as a member of the Board’s Audit Committee (the “Audit Committee”).
On May 27, 2024, the BLAC Board appointed Mr. Phil Geon Lee as a director, effective immediately.
On May 24, 2024, Steven Reed provided notice of his resignation as a member of the BLAC Board of Directors (the “ BLAC Board ”) effective immediately
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
Max materiality 1.00 · Median 0.65 · Most common event other_material